





(10)(2e) [sciensano.be]; (10)(2e) [sciensano.be]; (10)(2e) [bmg.gv.at]; (10)(2e)  
 (10)(2e) [sozialministerium.at]; (10)(2e) [sozialministerium.at]; (10)(2e)  
 (10)(2e) [sozialministerium.at]; (10)(2e) [sozialministerium.at]; (10)(2e) [ages.at]; (10)(2e) [ages.at];  
 TGV\_ssi.dk [(10)(2e)]@ssi.dk  
**Cc:** (10)(2e) [(10)(2e)]@idipaz.es; (10)(2e) [(10)(2e)]@gmail.com; (10)(2e)  
 (10)(2e) [(10)(2e)]@salud.madrid.org; (10)(2e) [(10)(2e)]@thl.fi  
**From:** (10)(2e)  
**Sent:** Tue 2/4/2020 1:43:58 PM  
**Subject:** FW: Support for nCoV laboratory diagnostics by SHARP/EMC

Dear SHARP partners,

For your information, please see the message and link below from our Spanish colleagues.  
 The European Commission is opening a call on coronavirus research under Horizon 2020.

[https://ec.europa.eu/info/news/coronavirus-eu-mobilises-eur10-million-for-research-2020-jan-31\\_en&pk\\_campaign=rtd\\_news](https://ec.europa.eu/info/news/coronavirus-eu-mobilises-eur10-million-for-research-2020-jan-31_en&pk_campaign=rtd_news)

**Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic**  
 ID: SC1-PHE-CORONAVIRUS-2020  
 Type of action: RIA Research and Innovation action  
 Deadline Model : single-stage  
 Opening: 30 January 2020  
 Deadline: 12 February 2020 17:00:00 Brussels time  
 Budget (EUR) (10)(2a) - Year : 2020

At this stage, THL has probably no capacity to join this initiative but if you are planning to take part, please keep (10)(2e)@thl.fi copied.

Kind regards,  
 (10)(2e) team

---



**From:** (10)(2e) [(10)(2e)]@idipaz.es  
**Sent:** 4. helmikuuta 2020 11:03  
**To:** (10)(2e)  
**Cc:** (10)(2e); (10)(2e)  
**Subject:** Re: Support for nCoV laboratory diagnostics by SHARP/EMC

Dear (10)(2e)

First of all, thank you very much for your email.  
 I contact you regarding the urgent call that the EU has launched regarding the CORONAVIRUS:

(10)(2g)

(10)(2g)

We wonder if you or some of the partners of SHARP are thinking to apply as coordinator in that call. We are positive that the expertise of the SHARP consortium can link perfectly with the scope of the call.

We think that SERMAS can be an important partner in this matter with our huge and solid expertise in this type of emergencies (EBOLA, Crimean-Congo fever, etc).

Please, if you know any possible potential coordinator, put in contact with us in order to try to participate in the proposal. Thank you very much for your help and we are looking forward to hearing from you soon.

Best regards,

(10)(2e)

(10)(2e)

(10)(2e)

(10)(2e)

Instituto de Investigación Sanitaria del Hospital Universitario La Paz - IdiPAZ  
 Paseo de La Castellana, 261

28046 - Madrid

Telf. (10)(2e)

Fax. (10)(2e)

Email. - (10)(2e) [@idipaz.es](mailto:@idipaz.es); (10)(2e) [@idipaz.es](mailto:@idipaz.es)

Este mensaje y sus archivos adjuntos son confidenciales y únicamente podrán ser usados por la persona o entidad a la que va dirigido. Este mensaje puede contener información confidencial o legalmente protegida. No hay renuncia a la confidencialidad o secreto profesional por cualquier transmisión defectuosa o errónea. Si usted ha recibido este mensaje por error notifíquelo inmediatamente al remitente.

#### Información básica sobre Protección de Datos:

- **Responsable:** Fundación para la Investigación Biomédica del Hospital Universitario La Paz
- **Finalidad:** Gestión de relaciones profesionales
- **Legitimidad:** Interés legítimo
- **Destinatarios:** Entidades y administraciones pública. Google LLC. Subencargado de Tratamiento fuera de la UE, acogido a Privacy Shield y cláusulas contractuales tipo
- **Derechos:** Acceder, rectificar y suprimir los datos, así como otros derechos, como se explica en la información adicional
- **Información adicional:** Puede consultar la [Información adicional y detallada sobre Protección de Datos](#) pinchando aquí

El jue., 30 ene. 2020 a las 13:54, (10)(2e) ([@thl.fi>\) escribió:  
 Dear SHARP partners,](mailto:@thl.fi)

Diagnostic assays for the detection of 2019-nCoV has been published and many of the SHARP partners and Member States have set up the diagnostics already. There are also mechanisms, e.g. through WHO, to send the samples to the reference laboratories for detection if needed.

SHARP wants to support it's partners and MS as well. Our SHARP partner, (10)(2e) (10)(2e) from the Erasmus MC has kindly offered their help in this, by providing real-time RT-PCR for detection. If you have suspected cases of 2019-nCoV and need support for the detection, you may send your samples to the EMC. SHARP will cover the costs for shipment of the samples if needed.

For sample types, shipment and more information: Please contact directly (10)(2e) (10)(2e) ((10)(2e) [@erasmusmc.nl\)\) or \(10\)\(2e\) \(\(10\)\(2e\) \[@erasmusmc.nl\\)\\).\]\(mailto:@erasmusmc.nl\)](mailto:@erasmusmc.nl)

If you wish to get compensation for costs of shipment of the samples, please contact THL ((10)(2e) [@thl.fi\)\) and check whether this needs to be added into the current amendment.](mailto:@thl.fi)

Kind regards,  
 (10)(2e) and (10)(2e) team



**SHARP Joint Action**

– Strengthened International HeAlth Regulations and Preparedness in the EU –

Contact the SHARP coordination team at THL, Finland: [\(10\)\(2e\)@thl.fi](mailto:(10)(2e)@thl.fi)

[www.sharpja.eu](http://www.sharpja.eu)

[www.thl.fi](http://www.thl.fi)

---

(10)(2e)  
Project Manager, PhD  
Infectious Disease Control and Vaccinations  
Unit  
Department of Health Security  
Finnish Institute for Health and Welfare (THL)  
P.O. Box 30, FI-00271 Helsinki, FINLAND

(10)(2e) @thl.fi  
Tel: (10)(2e)

